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The Challenges of Comparing a Clinically Validated Test to
Other Methods
To the Editor-in-Chief:
In the January 2012 issue of The Journal of Molecular
Diagnostics, Lade-Keller et al1 compared four research-use-
only BRAF mutation detection assaysdSanger sequencing,
pyrosequencing (PyroMark Q24 platform; Qiagen, Valen-
cia, CA), TaqMan and Competitive Ampliﬁcation of
Differentially Melting Amplicons (CADMA), and the CE-
IVD-marked and FDA-approved Cobas 4800 BRAF V600
Mutation Test (Cobas test; Roche Molecular Diagnostics
A/S, Hvidovre, Denmark)dfor their detection of BRAF
mutations within a serial dilution of DNA blends and 28
FFPE cutaneous melanoma samples. Although we agree that
improved assay performance is always critical to making
appropriate clinical treatment decisions, there were several
steps during this evaluation that may have impacted the
overall results.
The authors state that Sanger sequencing and the Cobas test
failed to detect mutations in a signiﬁcant proportion of the
samples, which contained small fractions of tumor cells. We
understand the challenges of obtaining adequate material for
method comparison studies from limited samples, and it is
important to adhere to each assay protocol to provide adequate
comparison data. Nevertheless, we agree with the authors that
the variability of tumor content estimation as reﬂected by thek
values obtained in the study may render different results and
that it is important to standardize pre-analytic procedures.
Though the authors state that macrodissection introduces an
additional step (required for samples with <50% tumor
content), this process has been successfully implemented in
numerous molecular laboratories that interrogate cancer
markers without disruption to the testing workﬂow. Despite
alternate DNA isolation and macrodissection, the Cobas test
had 100% concordance with the other assays for the identi-
ﬁcation of BRAF mutations that were 10% to 49% tumor
content by all tissue (nZ 9; four mutant samples) or by cell-
dense tissue (nZ 20; nine mutant samples). It has also been
shown that there is no direct correlation of percent tumor
content to percent mutant allele.2 Further assessment of the
low tumor content specimens should be performed to verify
percent mutant allele compared to threshold sensitivity for allCopyright ª 2013 American Society for Investigative Pathology
and the Association for Molecular Pathology.
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http://dx.doi.org/10.1016/j.jmoldx.2013.02.007assays. Published validation studies have shown that the
Cobas test has a >95% detection rate across formalin-ﬁxed,
parafﬁn-embedded tissue (FFPET) specimens with 5%
mutant alleles using 125 ng per PCR reaction, a DNA amount
typically obtained from a single 5 mm section.2 Tested across
multiple clinical sites, the Cobas test showed 100% repro-
ducibility between sites for all specimens tested with >5%
mutant alleles.3
We agree with the authors that molecular tests could
falsely classify other BRAF mutations, such as the c.1798_
1799GT>AA (V600K) mutation as c.1799T>A mutations.
TheCobas test can reliably detectV600Emutations in cell lines
and clinical FFPET specimens at>5%mutation level but does
display cross-reactivity to V600K at >31% mutation level.
Clinical and validation studies have shown that the Cobas test
can detect >66% of V600K mutations.2,3
It is difﬁcult to know the impact of the nonrecommended
DNA isolation method used for the Cobas test on the overall
assay performance. Surely, the burden on the lab would be
minimized if all DNA-based assays relied on a single,
uniﬁed, DNA isolation method. The Cobas test requires the
use of the Cobas DNA Sample Preparation Kit; however,
DNA was extracted from all FFPET samples in this study
with the Qiamp DNA FFPE Tissue Kit (Qiagen). In
a previous study, the Qiamp kit showed a similar nucleic
acid yield to the Cobas kit but with a higher level of RNA
contamination in nucleic acids isolated with the Qiamp kit.
Isolation of DNA from the Cobas kit resulted in signiﬁ-
cantly less PCR interference from contaminating RNA
relative to the Qiamp kit.4
Provision of accurate molecular diagnostic results that
impact treatment decisions is paramount to the success of
personalized health care strategies. The selection of patients
for targeted therapeutics based on companion diagnostics
could i) target the intended responder population whereas
spare nonresponder unnecessary treatment, ii) predict effec-
tive dosing, iii) monitor response to treatment, iv) identify
subgroups of a larger disease group that are eligible for treat-
ment due to a poor prognosis, and v)minimize the potential for
adverse drug events. Although technology drives molecular
assays toward greater sensitivity/performance, lab-validated
Correspondenceassays can appear to be equivalent to their approved counter-
parts. However, it is important to keep in mind the clinical
utility and reproducibility of testing methodologies. Analyti-
cally and clinically validated companion diagnostics, under
regulatory oversight, support issues of safety, utility, and
reliability for downstream clinical decisions.
Although this study was limited in terms of clinical
sample size, the collected assays showed good performance
relative to each other. The analytical performance of each
test across a comprehensive set of samples, multiple test
sites, operators, kits, and days will ultimately reveal the true
robustness of each of these assays. Such analytical studies
are required by pharmaceutical and diagnostic companies
and regulatory agencies to ensure the safety of patients. The
Cobas test has demonstrated excellent performance relative
to the decision for vemurafenib treatment in clinical stud-
ies.5e7 The improved clinical outcomes based on BRAF
mutation-positive samples from melanoma patients for
objective response rate and progression-free and overall
survival support the beneﬁt of the results from this clinically
reliable test.
John F. Palma
Felice Shieh
Roche Molecular Systems
Pleasanton, CaliforniaAuthor’s Reply:
We are grateful for the opportunity to respond to the
comments raised in the letter by Palma and Shieh. The
comments only concern our results using the Cobas 4800
BRAF V600 Mutation Test. The main issues raised were that
macrodissections were not performed to increase the
percentage of tumor cells for samples with<50% tumor cells
and DNA isolation was performed with the Qiamp DNA
FFPE Tissue kit.
Since pre-analytic procedures for the estimation of tumor
content have not been standardized,maygive rise to variability
in estimations made by different observers, are relative labor
intensive, and require a skilled pathologist, we found it
important to compare how different mutation testing meth-
odologies are affected by low tumor cell content. Therefore,
we decided not to perform macrodissections before DNA
isolation. Fromour study itwas clear that themore analytically
sensitive assays8,9 were less affected by low tumor content
compared to the less analytically sensitive assays.1 Thus, our
results underscore the notion that macrodissections should be
performed for sampleswith low tumor cell content when using
the Cobas test for diagnostic purposes.
To perform meaningful comparisons between the different
methods studied, it is important that the DNA samples tested
are the same for all methods. Furthermore, if DNA is ex-
tracted from different slides for each method, intratumor536heterogeneity with respect to BRAF-mutated cells would
be a confounding factor. In our study, we used the standard
method for DNA isolation in diagnostic molecular pathology
at the Department of Pathology at Aarhus University Hos-
pital (Aarhus, Denmark). After DNA isolation, we stan-
dardized the amount of DNA to what is recommended by
Roche using a NanoDrop ND-1000 spectrophotometer
(NanoDrop Technologies, Wilmington, DE). Also, the
Cobas test, despite alternate DNA isolation, had a 100%
concordance with the more analytically sensitive assays
(pyrosequencing, TaqMan, and CADMA) for the identiﬁ-
cation of BRAF mutations when tumor content was >10%.
Therefore, we do not believe that the overall results have
been impacted by the choice of DNA isolation procedure.
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